Treatment Combining Plasmapheresis and Pulse Cyclophosphamide in Severe Systemic Lupus Erythematosus

  • Johann O. Schroeder
  • Hans H. Euler
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 260)


The idea of curing a disease by removing harmful blood components from the patient’s circulation is almost as old as human ideas about medicine1. With the development of devices suitable for separating plasma from the cellular blood compartments — either by continous flow centrifugation or by membrane filtration — the technical preconditions were fulfilled for applying therapeutic plasmapheresis in man. In this procedure plasma containing noxious constituents is removed and replaced by a harmless substitute.


Systemic Lupus Erythematosus Lupus Nephritis Plasma Exchange Pulse Cyclophosphamide Antibody Synthesis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    H.E. Kainbic and Y. Nose, “Plasmapheresis, historical perspective. Therapeutic applications and new frontiers.” ISAO Press, Cleveland (1983) .Google Scholar
  2. 2.
    D. Koffier, V. Agnello, R. Thoburn and H.G. Kunkel, Systemic lupus erythematosus: Prototype of immune complex nephritis in man, J Exp Med. 134:169s (1971).Google Scholar
  3. 3.
    M. Mannik, Pathophysiology of circulating immune complexes. Arthritis Rheum. 27:783 (1982).CrossRefGoogle Scholar
  4. 4.
    J. A. Hardin, The lupus autoantigens and the pathogenesis of systemic lupus erythematosus. Arthritis Rheum. 29:457 (1986) .PubMedCrossRefGoogle Scholar
  5. 5.
    J. V. Jones, R. C. Bucknall and R. H. Cumming et al., Plasmapheresis in the management of systemic lupus erythematosus? Lancet 2; 709 (1976).CrossRefGoogle Scholar
  6. 6.
    J. V. Jones, R. H. Cumming and P. A. Bacon et al., Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus. Q J Med. 48:555 (1979).PubMedGoogle Scholar
  7. 7.
    J. V. Jones, M. F. Robinson, R. K. Parciany, L. F. Layfer and B. McLeod, Therapeutic plasmapheresis in systemic lupus erythematosus. Arthritis Rheum. 24:1113 (1981).PubMedCrossRefGoogle Scholar
  8. 8.
    R. Schlansky, R. J. Dehoratius, T. Pincus and K. S. K. Tung, Plasmapheresis in systemic lupus erythematosus. A cautionary note. Arthritis Rheum. 24:49 (1981).PubMedCrossRefGoogle Scholar
  9. 9.
    N. Wei, J. H. Klippel and D. P. Huston et al. , Randomised trial of plasma exchange in mild systemic lupus erythematosus. Lancet 1: 17 (1983) .PubMedCrossRefGoogle Scholar
  10. 10.
    H. F. Parry, L. J. Nineham and C. J. Moran et al., Plasma exchange in systemic lupus erythematosus. Ann Rheum Dis. 40:224 (1981).PubMedCrossRefGoogle Scholar
  11. 11.
    L. Kater, R.H.W.M. Derksen and F. A. Houwert et al., Effect of plasmapheresis in active systemic lupus erythematosus. Neth J Med. 24: 209 (1981).PubMedGoogle Scholar
  12. 12.
    C.M. Lockwood, S. Worlledge, A. Nicholas, C. Cotton and D. K. Peters, Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange. N Engl J Med. 300:524 (1979).PubMedCrossRefGoogle Scholar
  13. 13.
    J. V. Jones, Plasmapheresis in SLE. Clin Rheum Dis. 8:243 (1982).PubMedGoogle Scholar
  14. 14.
    J. D. Clough and L. H. Calabrese, Theoretical aspects of immune complex removal by plasmapheresis. Plasma Ther Transfus Technol. 2: 73 (1981).Google Scholar
  15. 15.
    American Society of Apheresis, Clinical applications of therapeutic apheresis. Report of the Clinical Applications Committee. J Clin Apheresis. 3:30 (1986).Google Scholar
  16. 16.
    K. H. Shumak and G. A. Rock, Therapeutic plasma exchange. N Engl J Med. 310: 762 (1984).PubMedCrossRefGoogle Scholar
  17. 17.
    J. V. Jones, J. D. Clough, J. R. Klinenberg and P. Davis, The role of plasmapheresis in the rheumatic diseases. J Lab Clin Clin Med. 97:589 (1981).Google Scholar
  18. 18.
    French Cooperative Study Group, A randomised trial of plasma exchange in severe acute systemic lupus erythematosus : Methodology and interim analysis. Plasma Ther Trans Tech. 6:535 (1985).Google Scholar
  19. 19.
    J. Clough, E. Lewis, J. Lachin and the Lupus Nephritis Collaborative Study Group, A controlled trial of plasmapheresis as adjunct to conventional therapy in severe lupus nephritis. Abstr. WAA, 2: 2–1 (1988).Google Scholar
  20. 20.
    J. W. Uhr and J. B. Baumann, Antibody formation. I. Suppression of antibody formation by passively administered antibody. J Exp Med. 113:935 (1961).PubMedCrossRefGoogle Scholar
  21. 21.
    H. Chang, S. Schneck, N. I. Brody, A. Deutsch and G. W. Siskind, Studies on the mechanism of the suppression of active antibody synthesis by passively administered antibody. J Immunol. 102:37 (1969).PubMedGoogle Scholar
  22. 22.
    M. W. Graf and J.W. Uhr, Regulation of antibody formation by serum antibody, I. Removal of specific antibody by means of immunoadsorption, J Exp Med. 131:1175 (1069) .Google Scholar
  23. 23.
    J.-C. Bystryn, M. W.Graf, J. W. Uhr, Regulation of antibody formation by serum antibody. II. Removal of specific antibody by means of exchange transfusion. J Exp Med. 132:1279 (1970) .PubMedCrossRefGoogle Scholar
  24. 24.
    J.-C. Bystryn, I. Schenkein and J. W. Uhr, A model for the regulation of antibody synthesis by serum antibody. Procr Immunol. 1:627 (1971).Google Scholar
  25. 25.
    B. C. Sturgill, and M. J. Worzniak, Stimulation of proliferation of 19S antibody-forming cells in the spleens of immunized guinea-pigs after exchange transfusion. Nature 228: 1304 (1970) .PubMedCrossRefGoogle Scholar
  26. 26.
    W. R. Bruce, B. E. Meeker and F. A. Valeriote, Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst. 37:223 (1966) .Google Scholar
  27. 27.
    H. H. Euler, L. Kleine, H. J. Gutschmidt and J. D. Herrlinger, Effect of early plasmapheresis and high-dose cyclophosphamide therapy in Goodpasture’s syndrome, in: “ Plasmapheresis in Immunology and Oncology” , J. H. Beyer, H. Borberg, C. Fuchs and G. A. Nagel eds., S. Karger, Basel (1982).Google Scholar
  28. 28.
    H. H. Euler, H. Löffler and E. Christophers, Synchronization of plasmapheresis and puis cyclophosphamide in pemphigus vulgaris. Arch Dermatol. 123: 1205 (1987).PubMedCrossRefGoogle Scholar
  29. 29.
    H. H. Euler, U. Krey, H. J. Gutschmidt and H. Löffler, Partial synchronization of plasmapheresis and immunosuppression in autoimmune diseases: Experimental and clinical results, in: “Therapeutic plasmapheresis: A critical look”, Y. Nosé, P. S. Malchesky and J. W. Smith eds., ISAO Press, Cleveland (1984) .Google Scholar
  30. 30.
    H.-J. Gutschmidt, H. H. Euler, J. Albrecht, F. Asbeck, L.H. Kleine, C.v. Klinggräff and H. Löffler, Cyclophosphamide stoss-therapy synchronized with plasmapheresis in rapidly progressive glomerulonephritis, Dtsch med Wschr. 111:1439 (1986).CrossRefGoogle Scholar
  31. 31.
    J. O. Schröder, H. H. Euler and H. Löffler, Synchronization of plasmapheresis and pulse cyclophosphamide in severe lupus erythematosus. Ann Int Med. 107: 344 (1987).Google Scholar
  32. 32.
    E. M. Tan, A. S. Cohen and J. F. Fries et al., The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25:1271 (1982) .PubMedCrossRefGoogle Scholar
  33. 33.
    M. H. Liang, S. Stern and J. M. Esdaile, Towards an operational definition of SLE activity for clinical research. Clin Rheum Dis. in press (1989) .Google Scholar
  34. 34.
    J. A. Schifferli, S. R. Bartolotti and D. K. Peters, Inhibition of immune precipitation by complement. Clin exp Immunol. 42:387 (1980).PubMedGoogle Scholar
  35. 35.
    J. Smolens, J. Stokes and A.B. Vogt, Human plasmapheresis and its effects on antibodies, J Immunol. 79:434 (1957) .PubMedGoogle Scholar
  36. 36.
    J. C. Roujeau, C. Andre, J. Revuz and R. Touraine, Effects of various immunosuppressive regimens on the “Rebound phenomenon” induced by plasma exchange in pemphigus, in: “Plasmapheresis. Therapeutic Applications and New Techniques”, Y. Nosé, P. S. Malchesky, J. W. Smith and R. S. Krakauer eds., Raven Press, New York (1983).Google Scholar
  37. 37.
    J. C. Guillaume, J. C. Roujeau and P. Morel et al., Controlled study of plasma exchange in pemphigus, Arch Dermatol. 124:1659 (1988).PubMedCrossRefGoogle Scholar
  38. 38.
    G. R. Barclay, M. Ayoub Greiss and S. J. Urbaniak, Adverse effect of plasma exchange on anti-D production in rhesus immunisation owing to removal of inhibitory factors. Br Med J. 280: 1569 (1980).PubMedCrossRefGoogle Scholar
  39. 39.
    J. P. Isbister, A. Ting and K. M. Seeto, Development of Rhspecific maternal autoantibodies following intensive plasmapheresis for Rh immunisation during pregnancy. Vox Sana. 33:353 (1977).CrossRefGoogle Scholar
  40. 40.
    J. Ludvigsson, L. Heding and G. Lieden et al., Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children. Br Med J. 286:176 (1983).CrossRefGoogle Scholar
  41. 41.
    J. Newsom-Davis, S. G. Wilson, A. Vincent and C. D. Ward, Long-term effects of repeated plasma exchange in myasthenia gravis. Lancet I: 464, (1979).CrossRefGoogle Scholar
  42. 42.
    Council on Scientific Affairs, Council Report, Current status of plasmapheresis and related techniques, Report of the AMA panel on therapeutic plasmapheresis, JAMA 253:819 (1985)Google Scholar
  43. 43.
    W. G. Barr , E. A. Hubbell and J. A. Robinson, Persistently active lupus erythematosus treated with intermittent plasmapheresis and bolus cyclophosphamide, in: “Proceedings of the first international congress of the world apheresis association: Therapeutic Plasmapheresis VI” T. Oda, Y. Shiokawa, N. Inoue, eds., ISAO-Press, Cleveland, (1987).Google Scholar
  44. 44.
    C. C. Zielinski, C. Müller and J. S. Smolen, A controlled study on the treatment of severe active systemic lupus erythematosus by plasmapheresis, in: EULAR Symposium Vienna, Abstr. 88 (1985).Google Scholar
  45. 45.
    H. A. Austin, J. H. Klippel and J. E. Balow et al., Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 314: 614 (1986).PubMedCrossRefGoogle Scholar
  46. 46.
    W. J. McCune, J. Golbus, W. Zeldes, P. Bohlke, R. Dunne and D. A. Fox, Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med. 318: 1423 (1988).PubMedCrossRefGoogle Scholar
  47. 47.
    J. C. Bystryn, Editorial: Plasmapheresis Therapy of Pemphigus, Arch Dermatol. 124:1702 (1988)PubMedCrossRefGoogle Scholar
  48. 48.
    R.H. W. Derksen, H.J. Schuurman, and F.H.J. Gmelig Meyling et al., Rebound and overshoot after plasma exchange in humans, J Lab Clin Med. 104:35 (1984).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • Johann O. Schroeder
    • 1
  • Hans H. Euler
    • 1
  1. 1.2nd Medical ClinicChristian-Albrecht University KielKiel 1Germany

Personalised recommendations